Stockscreener 앱 받기
4.42
3.70%
-0.17
시간 외 거래:
4.32
-0.10
-2.26%
전일 마감가:
$4.59
열려 있는:
$4.58
하루 거래량:
692.12K
Relative Volume:
0.87
시가총액:
$497.25M
수익:
$69.56M
순이익/손실:
$-240.05M
주가수익비율:
-1.4983
EPS:
-2.95
순현금흐름:
$-121.90M
1주 성능:
+8.33%
1개월 성능:
+36.84%
6개월 성능:
+294.64%
1년 성능:
+61.31%
1일 변동 폭
$4.30
$4.58
1주일 범위
$4.15
$4.74
52주 변동 폭
$1.05
$4.74
Adc Therapeutics Sa Stock (ADCT) Company Profile
명칭
Adc Therapeutics Sa
전화
41 21 653 02 00
주소
BIOPOLE, EPALINGES
ADCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
4.42 | 516.37M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 개시 | Guggenheim | Buy |
| 2023-08-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-04-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 개시 | CapitalOne | Overweight |
| 2022-11-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-08-17 | 재개 | Jefferies | Buy |
| 2021-08-09 | 개시 | RBC Capital Mkts | Outperform |
| 2021-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 개시 | Stifel | Hold |
| 2020-10-29 | 개시 | H.C. Wainwright | Buy |
| 2020-06-09 | 개시 | BofA/Merrill | Buy |
| 2020-06-09 | 개시 | Cowen | Outperform |
모두보기
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
Using flow based indicators on ADC Therapeutics SAJuly 2025 Technicals & Fast Exit Strategy with Risk Control - newser.com
What technical models suggest about ADC Therapeutics SA’s comeback2025 Short Interest & Fast Gaining Stock Reports - newser.com
Key metrics from ADC Therapeutics SA’s quarterly dataPortfolio Update Report & Low Risk Investment Opportunities - newser.com
Risk adjusted return profile for ADC Therapeutics SA analyzedJuly 2025 EndofMonth & Verified Technical Signals - newser.com
Using R and stats models for ADC Therapeutics SA forecastingMarket Growth Summary & Safe Capital Investment Plans - newser.com
What hedge fund moves indicate for ADC Therapeutics SA Common Shares stockMarket Growth Report & Daily Market Momentum Tracking - newser.com
ADC Therapeutics SA stock daily chart insightsJuly 2025 Intraday Action & Growth Focused Entry Point Reports - newser.com
ADC Therapeutics (NYSE:ADCT) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
ADC Therapeutics SA (NYSE:ADCT) Receives $7.75 Consensus PT from Brokerages - Defense World
ADC Therapeutics SA Hits New 52-Week High of $4.67 - Markets Mojo
ADC Therapeutics SA (NYSE:ADCT) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - 富途牛牛
ADC Therapeutics Gains Ground Ahead Of LOTIS-7 Expansion, LOTIS-5 Readout - RTTNews
ADC Therapeutics targets $600M–$1B peak revenue potential for ZYNLONTA amid strategic refocus and cost cuts - MSN
Analysts Offer Predictions for ADCT Q3 Earnings - Defense World
ADC Therapeutics SA Hits New 52-Week High of USD 4.31 - Markets Mojo
ADC Therapeutics (NYSE:ADCT) Sets New 52-Week HighStill a Buy? - MarketBeat
Order flow analysis tools used on ADC Therapeutics SAEntry Point & Low Drawdown Trading Strategies - newser.com
Understanding ADC Therapeutics SA’s price movementTrade Risk Assessment & Daily Technical Forecast Reports - newser.com
Analyzing recovery setups for ADC Therapeutics SA investorsMarket Risk Summary & Stepwise Trade Execution Plans - newser.com
Why analysts maintain buy rating on ADC Therapeutics SA Common Shares stock2025 Market Overview & Daily Risk Controlled Trade Plans - newser.com
ADC Therapeutics SA (NYSE:ADCT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
What is the fair value estimate for ADC Therapeutics SA Common Shares stock in 2025Take Profit & Fast Momentum Entry Tips - newser.com
Intraday pattern recognizer results for ADC Therapeutics SAPortfolio Risk Summary & Verified Entry Point Signals - newser.com
Platinum Investment Management Ltd. Cuts Stock Holdings in ADC Therapeutics SA $ADCT - MarketBeat
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire
ADC Therapeutics SA Hits New 52-Week High of USD 4.07 - Markets Mojo
ADC Therapeutics SA (NYSE:ADCT) Held Back By Insufficient Growth Even After Shares Climb 31% - Sahm
Exit strategy if you’re trapped in ADC Therapeutics SAPrice Action & AI Forecasted Entry/Exit Points - newser.com
ADC Therapeutics Updates Strategic Focus on ZYNLONTA - TipRanks
ADC Therapeutics : Corporate Presentation - MarketScreener
Adc Therapeutics Sa (ADCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Adc Therapeutics Sa 주식 (ADCT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 10% Owner |
Dec 11 '24 |
Buy |
3.04 |
100,000 |
304,500 |
13,145,712 |
| Redmile Group, LLC | 10% Owner |
Dec 04 '24 |
Sale |
2.07 |
25,352 |
52,479 |
15,566,731 |
5.74%
자본화:
|
볼륨(24시간):